OBJECTIVE: To investigate post-transplant immunotherapy with escalating donor-lymphocyte infusions (DLI) and novel agents (thalidomide, bortezomib, and lenalidomide) to target complete remission (CR). MATERIALS AND METHODS: Thirty-two patients with multiple myeloma who achieved only partial remission after allogeneic stem cell transplantation were treated with DLI. If no CR was achieved, one of the novel agents was added to target CR. RESULTS: CR defined either by European Group for Blood and Marrow Transplantation criteria, flow cytometry, or molecular methods as assessed by patient-specific immunoglobulin H-polymerase chain reaction or plasma cell chimerism polymerase chain reaction was accomplished in 59%, 63%, and 50% of patients, respectively. Achievement of CR resulted in improved 5-year progressive-free and overall survival, according to European Group for Blood and Marrow Transplantation criteria (53% vs 35%; p=0.03 and 90% vs 62%; p=0.06), flow cytometry (74% vs 15%; p=0.001 and 100% vs 52%; p=0.1), or molecular methods (84% vs 38%; p=0.001 and 100% vs 71%; p=0.03). CONCLUSIONS: Our finding demonstrates the clinical relevance of posttransplantation therapies to upgrade remission, and of remission's depth for long-term survival in myeloma patients.
OBJECTIVE: To investigate post-transplant immunotherapy with escalating donor-lymphocyte infusions (DLI) and novel agents (thalidomide, bortezomib, and lenalidomide) to target complete remission (CR). MATERIALS AND METHODS: Thirty-two patients with multiple myeloma who achieved only partial remission after allogeneic stem cell transplantation were treated with DLI. If no CR was achieved, one of the novel agents was added to target CR. RESULTS:CR defined either by European Group for Blood and Marrow Transplantation criteria, flow cytometry, or molecular methods as assessed by patient-specific immunoglobulin H-polymerase chain reaction or plasma cell chimerism polymerase chain reaction was accomplished in 59%, 63%, and 50% of patients, respectively. Achievement of CR resulted in improved 5-year progressive-free and overall survival, according to European Group for Blood and Marrow Transplantation criteria (53% vs 35%; p=0.03 and 90% vs 62%; p=0.06), flow cytometry (74% vs 15%; p=0.001 and 100% vs 52%; p=0.1), or molecular methods (84% vs 38%; p=0.001 and 100% vs 71%; p=0.03). CONCLUSIONS: Our finding demonstrates the clinical relevance of posttransplantation therapies to upgrade remission, and of remission's depth for long-term survival in myelomapatients.
Authors: Alexandra Gomez-Arteaga; Gunjan L Shah; Raymond E Baser; Michael Scordo; Josel D Ruiz; Adam Bryant; Parastoo B Dahi; Arnab Ghosh; Oscar B Lahoud; Heather J Landau; Ola Landgren; Brian C Shaffer; Eric L Smith; Guenther Koehne; Miguel-Angel Perales; Sergio A Giralt; David J Chung Journal: Biol Blood Marrow Transplant Date: 2020-07-23 Impact factor: 5.742
Authors: Sergio Giralt; Laurent Garderet; Brian Durie; Gordon Cook; Gosta Gahrton; Benedetto Bruno; Paremesweran Hari; Henk Lokhorst; Phillip McCarthy; Amrita Krishnan; Pieter Sonneveld; Harmut Goldschmidt; Sundar Jagannath; Bart Barlogie; Maria Mateos; Peter Gimsing; Orhan Sezer; Joseph Mikhael; Jin Lu; Meletios Dimopoulos; Amitabha Mazumder; Antonio Palumbo; Rafat Abonour; Kenneth Anderson; Michel Attal; Joan Blade; Jenny Bird; Michele Cavo; Raymond Comenzo; Javier de la Rubia; Hermann Einsele; Ramon Garcia-Sanz; Jens Hillengass; Sarah Holstein; Hans Erik Johnsen; Douglas Joshua; Guenther Koehne; Shaji Kumar; Robert Kyle; Xavier Leleu; Sagar Lonial; Heinz Ludwig; Hareth Nahi; Anil Nooka; Robert Orlowski; Vincent Rajkumar; Anthony Reiman; Paul Richardson; Eloisa Riva; Jesus San Miguel; Ingemar Turreson; Saad Usmani; David Vesole; William Bensinger; Muzaffer Qazilbash; Yvonne Efebera; Mohamed Mohty; Christina Gasparreto; James Gajewski; Charles F LeMaistre; Chris Bredeson; Phillipe Moreau; Marcelo Pasquini; Nicolaus Kroeger; Edward Stadtmauer Journal: Biol Blood Marrow Transplant Date: 2015-09-30 Impact factor: 5.742